ImmunityBio has surged over 200% YTD, yet I see little fundamental justification for its current $10B enterprise value. Click here to read why IBRX is a Sell.
With $21.9 million in Q3 revenue in magnet manufacturing, MP Materials is currently operating with high start-up costs ...
UK-based digital bank Revolut is reportedly eyeing a sale of shares in the second half of 2026 ahead of a potential public ...
The portfolio does not invest in the non-corporate credit market, and the sector saw strong performance in 2025, detracting ...
Nemetschek SE is rated a Buy with Q3/25 revenue up 15.8% y/y, EBIT up 33.9%, and free cash flow up 48.2%. Learn more about ...
Oruka Therapeutics, Inc. surged as ORKA-001 beat Skyrizi half-life in Phase 1; see psoriasis market upside, Phase 2a 2H26, ...
Range Nuclear Renaissance Index ETF offers a diversified, global exposure to the nuclear power sector. Click here to find out ...
To reflect the challenging environment in the U.S. and further weakness through the first half of the year, Diageo ( DEO) ...
Financials stocks like large banks are selling off due to increasing AI risks with many down year-to-date. AI disruption, ...
Ooops... Something went wrong while loading this page.
Lyft stock saw its worst single-day crash since late 2024 post-Q4 print. Click here to find out why I rate LYFT stock a Buy.
The EUR/USD pair is struggling for direction around the 1.1800 handle, with its next move dependent on the US dollar's ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results